HK inno.N Corp., formerly CJ Healthcare, said it has signed contracts to export its new gastroesophageal reflex disease (GERD) treatment, “K-Cab,” to Mongol and Singapore.

K-Cab, Korea’s No. 30 new drug, has been exported to 22 countries -- China, Vietnam, 17 Latin American countries, Indonesia, Thailand and the Philippines. 

HK inno.N has signed contracts to export K-Cab, a treatment for gastrointestinal reflux disease (GERD), to Mongol and Singapore.
HK inno.N has signed contracts to export K-Cab, a treatment for gastrointestinal reflux disease (GERD), to Mongol and Singapore.

K-Cab is a new type of potassium competitive acid blocker (P-CAB), which works faster than existing drugs and has longer persistence. Patients can take medicine before and after meals because of this benefit. 

HK inno.N recorded outpatient prescriptions worth 26.4 billion won ($24 billion) in 2019. An additional 58 billion won ($52 billion) in the first 10 months this year, to be ranked first in the GERD treatment market this year.

The company targets to launch the drug in Mongol next year, and Singapore by 2022. It will conduct differentiated clinical tests to expand the drug's indications from the existing four, including GERD, according to HK inno. N. 

“We are planning to find new partnerships with other Asian and European pharmaceutical companies to emerge as the world’s leading GERD treatment,” an official of HK inno. N said.
 

Copyright © KBR Unauthorized reproduction, redistribution prohibited